Patent · US Active

Polypeptides inhibiting CD40L

US11248055B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

Ablynx N.V. · BE

Inventors

Els Pattyn · Huise, BE
Ariëlla Van de Sompel · Oostakker, BE
Peter Meerts · Evergem, BE
Marie-Ange Buyse · Merelbeke, BE
Maarten Dewilde · Aalst, BE
Gerald Beste · Evergem, BE
Jaromir Vlach · Bonneville, FR
Jonathan Hsu · Cambridge, US

Key dates

Filing date	Nov 28, 2016
Grant date	Feb 15, 2022
Priority date	—
Expiry date	Sep 20, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to immunoglobulins that specifically bind CD40L and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of CD40L and are safe.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.